Funding for Faculty

Additional Details

RFP Snapshot: The Siteman Cancer Center (SCC) Biostatistics and Qualitative Research Shared Resource (BQSR) fulfills a critical function by providing methodologic and analytic support for the development and conduct of scientifically sound, innovative cancer research at SCC. Advances in biotechnologies and computing systems/software increasingly require specialized expertise and tools for sophisticated statistical methodologies. Qualitative research requires sound methods and approaches that support rigor and best practice. The overarching goal of the BQSR is to provide a comprehensive, centralized, and accessible biostatistics and qualitative support infrastructure for all phases of cancer research; from study development and design to data collection, ongoing monitoring, and final analysis.

Max Amount and Period: N/A

Eligibility: Must be a Siteman Cancer Center member.

Due Date: Rolling

Additional Details

RFP Snapshot: The WUSTL Center for Drug Discovery offer the CDD Match Grant15 and Grant25 programs.

Match Grant15 is to advance translational small-molecule drug discovery research at Washington University. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivopharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Match Grant25 is a follow-on award program meant only for those investigators who have successfully completed and met the objectives of a Match Grant15 (or the original CDD MicroGrant) award and request additional match funds to further advance the discovery research project. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in vivo pharmacokinetics for proof-of-concept in vivo pharmacology studies, intellectual property (patent) filing, and drug development.

Max Amount and Period:

Match Grant15 – $7,500 from CDD

Match Grant25 – $12,000 from CDD

Eligibility:

Match Grant15 – open to investigators with a faculty appointment at Washington University

Match Grant25 – open only to WashU faculty who have successfully completed a Match Grant15 (or CDD MicroGrant) and submitted a final research report.

Due Date: Rolling

Additional Details

RFP Snapshot: The purpose of the awards is to advance initial discovery pilots for Precision Health ICTS investigators. Proposals are not for developed projects but are to fund developmental or early stage work, including pilot data collection and analysis, in preparation for submission of future external funding.

Max Amount and Period: $25,000 for 1 year

Eligibility: Applicants must be full time faculty (instructor level or above) at Washington University in St. Louis or an ICTS partner institution. Applicant must be a member of the ICTS.

Due Date: Rolling

Additional Details

RFP Snapshot: The Just-In-Time (JIT) Core Usage Funding Program is designed to provide quick access to funding to use any of the JIT Cores (pdf) for research advancing medical knowledge that can improve human health. Siteman Cancer Center will co-sponsor cancer-focused proposals.

Max Amount and Period: Varies

Eligibility: Applicant must be a registered member of the ICTS and hold a faculty level appointment at WUSTL or an ICTS partner institution.

Due Date: Rolling

Additional Details

RFP Snapshot: There is a special emphasis on projects that accelerate existing preclinical and clinical research that increases therapeutic options, improves adjuvant therapies, delivers novel therapies focused on driver mutations (BRAF, TP53, KRAS, BRCA1, as examples) and investigate strategies to influence the tumor microenvironment (TME) to expand the use of immunotherapy. See RFA for other eligible research objective priorities.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applications will be accepted from non-profit, for-profit, and academic organizations, and from investigators who hold MD, PhD, or other professional degrees.

Due Date: Rolling

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This funding is geared toward studies about “upstream” causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals’ options and behaviors. Research should center on the needs and experiences of communities exhibiting the greatest health burdens and be motivated by real-world priorities. It should be able to inform a specific course of action and/or establish beneficial practices, not stop at characterizing or documenting the extent of a problem.

Max Amount and Period: No limit for 3 years, but budget must be reasonably supported by scope of project.

Eligibility: Applicant organizations must be based in the US or its territories. Preference will be given to applicant organizations that are either institutes of higher education, public entities, or nonprofits that are tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Due Date: Rolling

Additional Details

RFP Snapshot: Pioneering Ideas: Exploring the Future to Build a Culture of Health welcomes proposals that are primed to influence health equity in the future. We seek ideas that address any of RWJF’s Pioneering Ideas for an Equitable Future team’s four current areas of focus described below: 1) Future of Evidence; 2) Future of Social Interaction; 3) Future of Food; and 4) Future of Work. Additionally, under Open Exploration, also described below, this call for proposals seeks ideas that might fall outside of these four focus areas but which offer unique approaches to advancing health equity and our progress toward a Culture of Health.

Max Amount and Period: No limit for 3 years, but budget must be reasonably supported by scope of project.

Eligibility: Applicant organizations must be based in the US or its territories. Preference will be given to applicant organizations that are either institutes of higher education, public entities, or nonprofits that are tax exempt under Section 501(c)(3) of the Internal Revenue Code.

Due Date: Rolling

Additional Details

RFP Snapshot: Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care. We strive to fund treatment-based studies at the bedside, including all types of cancers. At Gateway, it is always and only about the patient. Involvement of patient advocates and patient advocacy groups in the design of the clinical trial, incorporating patient-reported outcomes and quality of life tools, and including patient advocates on research study review committees, are all ways to incorporate the patient’s unique perspective into the research study.

Max Amount and Period: $200,000-$1.5M over 2-5 years

Eligibility: Other available programs include:
• NCI/SPORE/P20 Program
• Integrative Research
• Society for Integrative Oncology (SIO)
• Decentralized Clinical Trial Initiative (DCTI)

Due Date: April 18, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

WUSTL is eligible to nominate TWO candidates for this opportunity.

RFP Snapshot: Gabrielle’s Angel Foundation funds the nation’s best science in the fields of leukemia, lymphoma, and related cancers of the blood. The Foundation focuses on projects for cancer prevention, detection, and treatment that are most likely to be translated into clinical trials within a three- to five-year period.

This call for applications will fund mainstream/conventional scientific research and integrative research projects. The Foundation accepts only one application per category/per institution:
• One Mainstream/Conventional Research Project
• One Complementary/Integrative Medicine Research Project

Max Amount and Period: $225,000 over 3 years

Eligibility: Applicants must have a PhD or MD, have a tenure track position, and be no more than five years in that position (although the five-year limitation is not meant to be a make-or-break qualification).
• Mainstream/Conventional: Applicants must hold the position of Assistant Professor.
• Complementary/Integrative: Applicants may hold the position of Assistant Professor OR Associate Professor.

Due Date: April 18, 2024 at 11:59PM CST

Application Assistance: Questions may be directed to [email protected].

Additional Details

WUSTL is eligible to nominate TWO candidates for this opportunity.

RFP Snapshot: Research applications must be focused on brain, breast, colorectal, endometrial, lung, ovarian, pancreatic or prostate cancer. Phi Beta Psi Sorority is a national, civic, non-profit organization whose National Project is to advance cancer research nationwide to improve prevention, diagnosis and treatment by providing research grants to qualified investigators addressing original questions and hypotheses to be explored in basic and clinical studies in the field of cancer.

Max Amount and Period: $60,000 for 1 year

Eligibility: Preference is given to Young Investigators with documented evidence of potential for conducting novel research of either basic or clinical aspects of cancer and cancer-related problems. Applications from Established Investigators exploring new and innovative areas of cancer research also will be considered. Post-doctoral fellows are not eligible. Research assistant professors may be eligible. The gold standard is as follows: if the individual is eligible to submit an R01 from their institution as Principal Investigator, then they are eligible to submit a Phi Beta Psi application.

Due Date: April 18, 2024 at 11:59PM CST

Application Assistance: Questions may be directed to [email protected].

Additional Details

WUSTL is eligible to nominate ONE candidate for this opportunity.

RFP Snapshot: This program provides support to junior interventional radiology faculty members early in their academic careers to allow time for the conduct of research. The goal of this grant is to have the recipient subsequently obtain additional funding from other peer-reviewed sources, (e.g., National Institutes of Health (NIH) grants). This funding mechanism is intended for junior IR faculty with dedicated research time. Applications should propose research that will advance the science of Interventional Radiology.

Max Amount and Period: $100,000 over 2 years

Eligibility: Applicants must be junior full-time faculty members (up to and including Assistant Professor level) and have a MD, DO, PhD, or equivalent degree. Applications from non-Society of Interventional Radiology (SIR) members will be considered, but such applications are required to have significant input and involvement by an SIR member. Applicants should not have any current grants exceeding $50,000. Applicants must be within the first five years of their initial faculty appointment after having completed all formal training. Applications will be accepted from citizens of the United States or Canada or those who have permanent resident status therein. Applicant must have the support of their Chair and must have a mentor at the level of Assistant Professor or higher.

Due Date: April 22, 2024 at 11:59PM CST

Application Assistance: Questions may be directed to [email protected].

Additional Details

RFP Snapshot: Gateway is dedicated to supporting the next generation of academic-based clinical investigators who are developing investigator-initiated trials (IITs). At our follow up Gateway Clinical Trial Accelerator Program (GAP) session, applicants will have the opportunity to pitch their novel IIT idea live in front of members from the Gateway Scientific Peer Review Committee and clinical trialists with a chance to win the $50,000 GAP Award.

Max Amount and Period: $50,000 for 1 year

Eligibility: Applicants must be at the Assistant Professor level, must have a doctoral degree, and must be able to attend the live session being held at the Hyatt Regency McCormick Place in Chicago (the hotel attached to McCormick Center where the 2024 ASCO Annual Meeting is being held).

Due Date: Letter of Intent Due: April 22, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Proposed projects should examine both the resources required and monetary and non-monetary returns on the investment in PROMs programs. This grant is meant to support studies investigating the value of using patient-reported outcome measures (PROMs) in oncology clinical practice for individual patient care. Projects should investigate the use of PROMs in adult cancer patients. Proposals must include patients with breast cancer and/or prostate cancer and/or hematologic malignancies; however, applications do not have to focus solely on those disease areas. For example, proposals that include breast cancer along with other solid tumors are considered within scope.

Max Amount and Period: $100,000 for 1 year

Eligibility: The applicant must have the expertise and data access necessary to conduct the proposed project successfully. In general, the applicant PI will be expected to have a medical or postdoctoral degree (MD, PhD, or equivalent). Applicants with a Master’s degree in a relevant field and sufficient experience will be considered. A multidisciplinary team is encouraged, and should include both clinical and methodologic expertise aligned with the proposal objectives, as well as patient partners.

Due Date: Letter of Intent Due: April 25, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This award is intended to shape the future of cancer survivorship treatment and care. We invite applications that focus on improving the quality and quantity of life for childhood, adolescent and young adult cancer survivors. Our goal is to support development of interventions that prevent, minimize and address the late effects of cancer therapies. Proposals to develop drugs or modalities meant to mitigate late effects, as the sole or primary focus, are eligible. Proposals to develop therapeutic approaches (new drugs, modalities, or regimens for treating cancer) are not eligible to apply. In addition, projects that propose to translate basic research into interventions, regardless of whether these take place during active therapy or later, are encouraged.

Max Amount and Period: $250,000 over 2 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator (PI(s)) is invited to work with his/her organization to develop an application for support. Applicants need not be American citizens; however, they must have a paid appointment at an academic, medical, or research institution in the United States. Generally, all tenured and tenure-track Assistant, Associate, and Full Professors, as well as all Research Assistant Professors, Research Associate Professores, Research Professors, and Clinical Professors. All Adjunct, Visiting, Emeritus, Lecturer, or other faculty must have the approval of their Department and Dean of the relevant School or College.

Due Date: Letter of Intent Due: April 26, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: CCRF wishes to support research that reduces health disparities or inequities in childhood cancer incidence, presentation, access to care, outcome of therapy including adverse event rates, or survivorship. Health disparities are defined here as “systematic, plausibly avoidable health differences adversely affecting socially disadvantaged groups.” (Braveman et al. 2011). CCRF will consider disparities based on race/ethnicity, sex or gender, socioeconomic status, language, geography, or other social determinants of health, so long as their evaluation is supported by the literature. Proposals that identify modifiable risk factors, elaborate mechanisms of disparities or inequities, or which plausibly propose to reduce them, will have greater priority for funding than proposals that simply describe them.

Max Amount and Period: $250,000 over 2 years

Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator (PI(s)) is invited to work with his/her organization to develop an application for support. Applicants need not be American citizens; however, they must have a paid appointment at an academic, medical, or research institution in the United States. Generally, all tenured and tenure-track Assistant, Associate, and Full Professors, as well as all Research Assistant Professors, Research Associate Professores, Research Professors, and Clinical Professors. All Adjunct, Visiting, Emeritus, Lecturer, or other faculty must have the approval of their Department and Dean of the relevant School or College.

Due Date: Letter of Intent Due: April 26, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This mechanism is meant to provide grants for clinical repurposing trials led by underresourced researchers and clinicians based in low and lower-middle income countries (LMICs), as defined by the World Bank (see https://data.worldbank.org/products/wdi-maps) to impact LMIC-based patients. Specifically, this RFP is seeking clinical repurposing trials to address any unsolved disease facing patients in LMICs. CWR is interested in building capacity for clinical research in LMICs while finding available and affordable treatments for patients in LMICs through repurposing research. CWR has a preference for trials that address high disease burden.

Max Amount and Period: $65,000 for 1 year

Eligibility: Eligible applicants must be located at institutions in LMICs that have received previous external, third-party clinical research fundingn from government, NGO, private foundations, or other sources. Applicant institutions must have past or current experience with human clinical research and priority will be given to institutions with established collaborations with institutions in high income contries. Eligible treatments must be a drug, device, nutraceutical, or indigenous medicine and must be already approved by the FDA, EMA, or other regulatory body. The treatment must also be available in generic form in the country where the research will be conducted and not under any patent protection anywhere in the word.

Due Date: Letter of Intent Due: April 26, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio. Projects for this award must be centered on evidence-based laboratory, data, and/or medical science.

Max Amount and Period: $750,000 over 3 years

Eligibility: Applicants must be within three to eight years from the start of an independent faculty research appointment as of 12/31/2024. Applicants must have MD, PhD, or equivalent. Applicants must demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review process. Proposed projects must not be supported by other sources of funding.

Due Date: Letter of Intent Due: April 29, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This grant is meant to support investigators in the US proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Max Amount and Period: No Limit for 1 year (budget must be reasonably supported by scope of project)

Eligibility: Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure. Post-docs who are on the tenure track and have a tenured mentor are eligible.

Due Date: April 30, 2024 at 5PM CST

Application Assistance: Washington University faculty may reach out to Danny Jaschek in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful.

Max Amount and Period: $75,000 for 1 year

Eligibility: The applicant must be a current or former ACS grantee (includes IRG pilot grant awardees) or a former ACS postdoctoral fellow. Applicants must have a full-time faculty appointment and may be at any career stage.

Due Date: April 30, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This award is designated for ASH members who applied for an NIH R01 grant or equivalent and were scored but not funded. ASH Bridge Grants are intended to help sustain recipients’ research and contribute to their retention in hematology investigation while they reapply.

Max Amount and Period: $150,000 for 1 year

Eligibility: Applicants must be ASH members, hold a faculty position, and must have submitted to the NIH in the past 18 months (from the review date) a hematology-related R01 or R01-equivalent application that was scored but not funded. Applicants must have the commitment of his/her institution to match $50,000 in funds. Also, at the time of award activation, applicants may not have any more than $250,000 annually in other research funding. This amount does not include the applicant’s salary/fringe or funding from within the institution.

Due Date: May 1, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This award is to support research on a topic related to physiatric rehabilitation for individuals with cancer-related disability. Special consideration will be given to applications focused on outcomes and/or comparative effectiveness research.

Max Amount and Period: $10,000 for 1 year

Eligibility: The applicant and/or at least one co-investigator must be a member of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) or the Association of Academic Physiatrists (AAP).

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The PhRMA Foundation Faculty Starter Grant in Drug Discovery offers financial support to individuals beginning independent careers in drug discovery research at the faculty level at an accredited U.S. university. Applicants must be within the first three years of their independent status. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be full-time, promotion eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited US university. Applicants must be within the first three years of independent status at award activation. Applicants should not have other substantial sources of research funding. Individuals receiving only intramural funding or start-up funding from the university are eligible to apply.

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The PhRMA Foundation Faculty Starter Grant in Drug Delivery offers financial support to individuals beginning independent careers at the faculty level at an accredited U.S. university in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering. Applicants must be within the first three years of their independent status.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be full-time, promotion eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited US university. Applicants must be within the first three years of independent status at award activation. Applicants should not have other substantial sources of research funding. Individuals receiving only intramural funding or start-up funding from the university are eligible to apply.

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The PhRMA Foundation Faculty Starter Grant in Translational Medicine offers financial support to individuals beginning independent research careers at the faculty level at an accredited U.S. university. Applicants must be within the first three years of their independent status. The PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.

Max Amount and Period: $100,000 for 1 year

Eligibility: Applicants must be full-time, promotion eligible, research-intensive faculty at a PhD and/or MS degree-granting accredited US university. Applicants must be within the first three years of independent status at award activation. Applicants should not have other substantial sources of research funding. Individuals receiving only intramural funding or start-up funding from the university are eligible to apply.

Due Date: May 1, 2024 at 11AM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

WUSTL is eligible to nominate TWO candidates for this opportunity.

RFP Snapshot: The Catalyst Research Award Program is designed to provide seed funding to support translational research that can be transferred to clinical practice in the near term (3-5 years). The award supports planning and development of projects, teams, tools, techniques, and management infrastructure necessary to lay the foundation for a subsequent two to three year $1M Transformational Award. The program supports high-risk, high-reward projects aimed at overcoming scientific and therapeutic challenges. Successful projects are expected to pave the way for new disease treatments and cures. Applications must demonstrate high translational potential, include achievable milestones with significant impact on improving lives, and align with one of the three following focus areas:

• Identifying biological markers
• Therapeutic targets
• Developing agents to disrupt or prevent diseases

Max Amount and Period: $350,000 over 1-2 years

Eligibility: The lead applicant must have institutional support, necessary facilities, and independence as an investigator. No funding support for a similar project is allowed for applicants and key personnel. U.S. citizenship and visa documentation are not mandatory. Collaborations across disciplines, including both PhD and MD researchers, are encouraged to address roadblocks and achieve critical research objectives efficiently.

Due Date: May 1, 2024 at 11:59PM CST

Application Assistance: Questions may be directed to [email protected].

Additional Details

RFP Snapshot: The goal of the program is to provide seed grants for high-risk, high-reward projects focused on ROS1+ cancers. Projects focused on pre-clinical, translational, or clinical research of ROS1+ cancers will be considered. See RFA for full list of possible research topics.

Max Amount and Period: $75,000 for 1 year

Eligibility: The applicant must be an independent, self-directed researcher for whom his/her institution must provide space and other resources customary for independent investigators. The application must convey the commitment of the institution to the applicant and the proposed research activities. Applicant must hold a doctoral degree and faculty appointment.

Due Date: Letter of Intent Due: May 3, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: ADAPT aims to bring together researchers in systems biology, bioinformatics, mathematical modeling, and oncology to address the challenge of treating ever-changing metastatic cancer. To meet this goal, the ADAPT program invites proposals to three technical areas. Technical area 1 focuses on therapy recommendation techniques, including multi-modal data fusion, resistant trait modeling, and development of biomarkers to predict drug response. Technical area 2 focuses on a new evolutionary clinical trial that treats patients during multiple therapy lines by discovering emergent resistant traits and therapy biomarkers developed in technical area 1. Technical area 3 unites researchers and clinicians through the creation of a cancer treatment and analysis platform to enable real-time data availability. The goal of the program is to accurately predict which patients will respond to which therapies, improving survival in people with metastatic cancers.

Max Amount and Period: Varies

Eligibility: All responsible sources capable of satisfying the Government’s needs may submit a proposal to a Module Announcement. Specifically, universities, non-profit organizations, small businesses and other than small businesses are eligible and encouraged to propose to Module Announcements.

Due Date: May 10, 2024 at 12 Noon CST

Application Assistance: Washington University faculty are encouraged to contact Nicole Moore in OVCR at [email protected] for guidance on applying.

Additional Details

RFP Snapshot: The Yosemite-American Cancer Society Award supports innovative research to develop methodologies, establish feasibility, or pilot high risk/high reward projects to advance the prevention, diagnosis, or treatment of cancer. Preliminary data are not required. Priority will be given to projects that are highly innovative, feasible within a two-year maximum timeframe, and are poised to make an impact on cancer prevention, treatment, and healthcare delivery.

Max Amount and Period: $300,000 over 2 years

Eligibility: WUSTL has been invited to submit an application in response to this RFA. Investigators at any career stage with a faculty appointment or full-time employment position at WUSTL are eligible to apply.

Due Date: May 10, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This award is designed to support the career development of early-stage investigator physicians who are underrepresented in medicine, and physicians who have demonstrated a commitment to increasing diversity in clinical research.

Max Amount and Period: $240,000 over 2 years

Eligibility: Eligible applicants must identify with one or more of the following racial/ethnic groups: African American or Black, Hispanic or Latinx, American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or Southeast Asian OR must have demonstrated a commitment to increasing diverse patient participation in clinical trials. Applicants must be US citizens or Lawful Permanent Residents. Applicants must hold the degree of MD, MD/PhD, DO, or DO/PhD and have completed their terminal degrees within the past 10 years. They must also not have any substantial NIH research grants.

Due Date: May 12, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia & AACR is intended to fund innovative research projects in breast and gynecologic cancers and to invest in the next generation of female early-stage scientists domestically and globally. The aim of this award is to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of breast and gynecologic cancers with the goal of eliminating cancer health disparities and improving patient outcomes. The research proposed for funding may be in basic, translational, clinical, or population sciences.

Max Amount and Period: $206,000 over 2 years

Eligibility: Applicants must be female investigators with a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants belonging to racial or ethnic groups shown to be underrepresented in the cancer-related sciences workforce are especially encouraged to apply. Applicants must hold a position of Assistant Professor and must have started their first independent faculty position within the past 6 years from the grant start date. Applicants must devote at least 75% of their total effort to research in breast or gynecological cancers.

Due Date: May 15, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: Freeman Hrabowski Scholars will be outstanding basic researchers, including physician-scientists, who have strong potential to become leaders in their fields and to advance diversity, equity, and inclusion through their mentoring efforts and understanding of systemic exclusion and marginalization in science of trainees from different backgrounds. Scholars will prioritize scientific excellence in their own research while creating an inclusive lab climate that serves as a model within their own institutions and beyond. Eligible research areas are in the biological and biomedical sciences and include many scientific disciplines in a wide range of organisms.

Max Amount and Period: $8.6M over 10 years (full salary and benefits – $400,000/year for first 5 years and $600,000/year for second 5 years)

Eligibility: Applicants must hold a PhD and/or MD (or equivalent). They must have begun their first post-training position and tenure-track (or equivalent) faculty position on or after 3/1/2020, or have accepted an offer for a tenure-track (or equivalent) position that will begin no later than 3/1/2025. Applications are encouraged from individuals of all backgrounds, including members of groups underrepresented in science and from institutions not previously affiliated with HHMI.

Due Date: May 15, 2024 at 2PM CST

Virtual Webinar (60 min): March 4, 2024 at 1PM CST – Register today to learn more about the 2025 competition. Link to register: https://hhmi.zoom.us/webinar/register/WN_SO-DMM2XQymG1tibQFreyQ

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Route 66 SPORE in Endometrial Cancer CEP focuses on recruiting and supporting early career and established investigators in translational endometrial cancer research. The CEP builds upon existing productive collaborations between outstanding researchers with expertise in translational endometrial cancer at Washington University, University of New Mexico, and University of Oklahoma. The program will further enhance these collaborations by providing funding support, didactic training, career development and mentoring to new investigators in the field.

Max Amount and Period: $50,000 for 1 year
Budget requests up to $75,000 will be considered with a unique scope of work and strong budget justification. Award may be renewed for second year with adequate progress and availability of funds (max 2 years).

Eligibility: Early career faculty or established investigators who wish to develop or refocus their careers on translational research in endometrial cancer with emphasis on etiology, prevention, diagnosis, early detection, treatment, endometrial cancer disparities, or population science. Senior level post-doctoral or clinical fellows who provide a letter from their Department Chair or Division Director stating that candidate will join its faculty by 08/01/2024. Awardees must be faculty members from one of the partner institutions: Washington University, University of New Mexico, University of Oklahoma Health Sciences Center. Faculty from NIH-defined minorities underrepresented in biomedical research are specifically encouraged to apply.

Due Date: May 15, 2024 at 5PM CST

Application Assistance: Questions may be directed to Veronica Davé, PhD at [email protected].

Additional Details

RFP Snapshot: The Route 66 SPORE in Endometrial Cancer DRP focuses on supporting innovative, early-stage research in endometrial cancer, to develop pilot projects to the point of inclusion as full SPORE projects, to increase the number of investigators committed to endometrial cancer, and to diversify the workforce.

Max Amount and Period: $50,000 for 1 year
Budget requests up to $75,000 will be considered with a unique scope of work and strong budget justification. Award may be renewed for second year with adequate progress and availability of funds (max 2 years).

Eligibility: Independent faculty members (Instructor level or higher at the time of award) from any of the three partner institutions: Washington University, University of New Mexico, University of Oklahoma Health Sciences Center. Faculty from NIH-defined minorities underrepresented in biomedical research are specifically encouraged to apply.

Due Date: May 15, 2024 at 5PM CST

Application Assistance: Questions may be directed to Veronica Davé, PhD at [email protected].

Additional Details

RFP Snapshot: This NOSI encourages eligible grantees to apply for administrative supplements to support cancer research career development of early-stage Low- and Middle-Income Country (LMIC) investigators (ESLIs). The NCI Global Oncology Mentored Research Supplement initiative is designed to support high-quality mentored research experiences for ESLIs within the context of NCI extramural research projects. The overarching goal of this supplement is to strengthen the capacity of LMIC investigators to conduct high-quality independent and/or collaborative research in their home institutions thereby generating context-appropriate evidence to address the growing cancer problem in LMICs.

Max Amount and Period: $125,000 for 1 year

Eligibility: Eligible Parent Awards: R01, R35, R37, P01, P20, P50, U01, U19, U54, UH2, UH3, UG1, UG3 or UM1

Due Date: May 15, 2024 at 5PM CST

Additional Details

RFP Snapshot: SAA is awarding two (2) research grants focused on gene and base editing techniques. Research proposals should focus on application and/or improvement of current gene editing techniques (such as CRISPR-Cas) in advancing cancer research including early detection, diagnostics, and treatments including targeted therapies, immunotherapies, and cellular therapies.

Max Amount and Period: $450,000 over 2 years

Eligibility: The applicant must have a MD, PhD, MD/PhD or equivalent degree and a full-time academic appointment at the level of Assistant Professor or higher. The research group must have sufficient expertise in gene editing at the start of the project. This grant is not intended to assist in developing new uses of gene editing techniques.

Due Date: Letter of Intent Due: May 15, 2024

Application Assistance: Washington University faculty may reach out to Amy Smith, Executive Director of Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This grant is meant to stimulate highly innovative research from young investigators into the subject of triple negative breast cancer. This grant mechanism is intended to promote and support creative, paradigm shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. While the research proposed for funding may be basic, translational, or clinical in nature in any area of cancer research, the 2024 TNBCF-AACR NextGen Grant will be awarded only to triple negative breast cancer-focused projects.

Max Amount and Period: $450,000 over 3 years

Eligibility: Applicants must hold a tenure-eligible appointment at the rank of Assistant Professor. Research Assistant Professor, Adjunct Assistant Professor, Assistant Professor Research Track, Visiting Professor, or Instructor are not eligible. Applicants must not have held this Assistant Professor position for more than three years. Applicants must be active AACR members, have a PhD, MD, MD/PhD, and not currently be a candidate for a further doctoral degree.

Due Date: Letter of Intent Due: May 16, 2024 at Noon CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Washington University faculty may also reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of the Preclinical Hub (PCH) Program is to stimulate NF drug discovery by funding the development of relevant and translational preclinical tools to support drug screening efforts as part of the Preclinical Hub model, which will serve to provide access to NF-focused tools and resources for the purposes of drug development. Proposals should focused on the generation of clinically-relevant in vitro (cell-based) or in vivo (whole animal) model systems for NF.

Max Amount and Period:

$375,000 over 3 years
for development and/or validation of an in-vivo model

$225,000 over 3 years
for development or validation of a cell-based model

Eligibility: Applicants should have an MD, PhD, or equivalent degree and should already have established in their laboratory, or have identified collaborators with, all required resources including in vivo and in vitro models.

Due Date: May 20, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of this mechanism is to fund clinical trials that are innovative, focus on cancers that are either underfunded or under-researched, and provide better quiality of life or symptom relief than current treatments.

Max Amount and Period: $200,000 over 3 years

Eligibility: Applicants must be at the Assistant Professor level or higher and have MD, DO, or MD/PhD degree. Preclinical studies must be complete. Applicant must be affiliated with a clincial department capable of supporting the proposed research.

Due Date: Letter of Intent Due: June 1, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of this mechanism is to fund innovative research that is within 2-3 years of translation to a clinical trial or is already associated with a clinical trial, focus on cancers that are either underfunded or under-researched, and provide better quality of life or symptom relief than current treatments.

Max Amount and Period: $100,000 over 3 years

Eligibility: Applicants must have an MD, DO, or MD/PhD degree and be within 5 years of completing a training fellowship in pediatric hematology/oncolgy or a closely related discipline. Applicants must be at the level of Instructor or higher and be affiliated with a clincial department capable of supporting the proposed research.

Due Date: Letter of Intent Due: June 1, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of this mechanism is to fund programs that expand and enhance a clinical trial’s capability to provide clinical education opportunities, provide services/infrastructure for oncology patients in clinical trials, and expand patient population to ensure diverse and equitable access (please see the Health Equity Statement in the RFA for more detail).

Max Amount and Period: $65,000 over 2 years

Eligibility: Applicants must be at the Assistant Professor level or higher and have MD, DO, or MD/PhD degree. Applicant must be affiliated with a clinical department capable of translating the proposed research.

Due Date: Letter of Intent Due: June 1, 2024 at 4PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The Pancreatic SPORE CEP focuses on supporting innovative, early-stage research in endometrial cancer, to develop pilot projects to the point of inclusion as full SPORE projects, to increase the number of investigators committed to endometrial cancer, and to diversify the workforce.

Max Amount and Period: $150,000 – $200,000 over 2 years

Eligibility: Junior faculty (Instructor or Assistant Professor) without R01 or equivalent grant are eligible. In addition, senior post-doctoral fellows (PhD, MD, or MD- PhD) who have a written commitment from their department chair indicating promotion to Instructor or Assistant Professor by the time of the award (08/01/2024).

Due Date: June 1, 2024 at 5PM CST

Application Assistance: Questions may be directed to Christina Kasting at [email protected].

Additional Details

RFP Snapshot: The Pancreatic SPORE DRP focuses on supporting innovative, early-stage research in endometrial cancer, to develop pilot projects to the point of inclusion as full SPORE projects, to increase the number of investigators committed to endometrial cancer, and to diversify the workforce.

Max Amount and Period: $75,000 – $100,000 for 1 year

Eligibility: All faculty members (Instructor level or higher) or senior post-doctoral fellows who will be promoted to faculty by 08/01/2024. Preference will be given to junior faculty or established investigators with a new translational pancreatic cancer research focus.

Due Date: June 1, 2024 at 5PM CST

Application Assistance: Questions may be directed to Christina Kasting at [email protected].

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ( de-implement ) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Max Amount and Period: No limit over 5 years, but must reflect needs of project

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ( de-implement ) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Max Amount and Period: $275,000 over 2 years

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

Additional Details

RFP Snapshot: The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ( de-implement ) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Max Amount and Period: $100,000 over 2 years

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

Additional Details

RFP Snapshot: This Notice of Funding Opportunity (NOFO) will support innovative, collaborative, and interdisciplinary research focused on clinical epidemiology, evaluation of public and/or health care policies, and validation of measurements that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.

Max Amount and Period: No limit over 5 years, but must reflect needs of project

Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

Due Date: June 5, 2024 at 5PM CST

Application Assistance: Washington University faculty may reach out to Sarah Van Vickle-Chavez in Public Health Sciences at [email protected] with any questions and for assistance with the proposal, including gathering pertinent catchment statistics regarding disparities.

Additional Details

RFP Snapshot: The purpose of this program is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. Applicants must have an original project that is not currently being funded that has a clear focus on accelerating the discovery of more effective, less toxic therapies for childhood cancers. Research projects should address a testable hypothesis based on strong scientific rationale. Applicants must be first-time recipients of a pediatric cancer research-focused NIH R01 award or equivalent independent award.

Max Amount and Period: $800,000 over 4 years

Eligibility: Applicants must have an MD, PhD, or MD/PhD (DO, MBBS or equivalent) and be within ten years of their first faculty appointment at the Assistant Professor level or higher at the time that their application is submitted. Applicants must be recipients of their first independent award such as R01 and must be within five years of notice of award of this award or its equivalent. R01 equivalent NIH awards include the DP1, DP2, DP5, R37, R56, RF1, RL1, U01 and selected R35 activity codes. Applicants with a K99/R00 award are eligible, if the PI is in the first year of the R00 phase of the award at the time of submission.

Due Date: June 6, 2024 at 7PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The purpose of this program is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to scientists focused on pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A mentor is required, and a career development
plan must be included.

Max Amount and Period: $800,000 over 4 years

Eligibility: Applicants must have an MD, PhD or MD/PhD (DO, MBBS or equivalent) and be within ten years of their terminal degree and five years of their first faculty appointment as an Assistant Professor at the time that their application is submitted. More senior Assistant Professors, as well as Associate and Full Professors, are ineligible. If still at the Instructor level, the applicant must have a firm commitment from the Department Chair/Division Chief at the time of grant submission for an Assistant Professor position within one year of receiving the award. A minimum of 75% of the applicant’s time must be allocated as non-clinical protected time for all research activities. A mentor must be identified from the applicant’s home institution. Applicants may not be the PI of a K99/R00 or other nationally-competitive award such as an R01 or equivalent, P, or U award. Applicants cannot have 2 R21s or 2 R03s at any time before the award.

Due Date: June 13, 2024 at 7PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The goal of the Prevent Cancer Foundation’s research program is to identify and to provide seed funding for innovative projects with the potential to make substantial contributions to cancer prevention or early detection. By funding the most promising research, including fellowship projects led by early career scientists, we contribute to important advances in cancer prevention and early detection. Research projects will be aimed at reducing the frequency of neoplasms including but not limited to brain, bladder, breast, colon and rectum, endometrium, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin (including melanoma), stomach as well as HPV-related cancers and hematologic malignancies.

Max Amount and Period: $100,000 over 2 years

Eligibility: The goal of the Foundation’s research program is to provide seed funding for innovative projects expected to lead to future funding from other peer-reviewed sources. All application must demonstrate substantial near-term potential for impact on cancer prevention or early detection. Pre-clinical research with clear applicability to cancer prevention/early detection is acceptable, provided a translational relationship is evident within 5 years.

Due Date: June 14, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This award will support innovative patient-centered research designed to address critical problems or barriers to progress in the field of brain tumor QoL. The proposed scope of work must include brain tumor research focused on one of the following topics or a combination of the two:
● Supportive and palliative care
● Patient and family brain tumor-related navigation

NBTS welcomes proposals that focus on research questions relevant to QoL for people with brain tumors and their care partners. Projects should focus on research that will work towards 2 improving patient outcomes and that can provide the foundation for future research projects.

Max Amount and Period: $200,000 over 2 years

Eligibility: Applicants must hold a clinical doctoral degree (e.g., MD, DO) or doctoral degree (e.g., PhD, MD, DrPH) from an accredited institution. They must hold an independent position at an accredited institution and may be at any career stage.

Due Date: Letter of Intent Due: June 15, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This training is intended for trainees and junior faculty engaged in laboratory-based translational and basic science research. Trainees and faculty holding MDs, MD/PhDs, biomedical PhDs, or pharmacy PharmDs (or equivalents) are encouraged to apply.

Max Amount and Period: Week-long course held in spring, year-long mentoring

Eligibility: Applicants must be a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents) in basic and translation research in classical or malignant hematology. MD applicants must be within twelve years of post-graduation at the time of the deadline for full application. PhD applicants must have less than eight years of post-doc experience after graduation at the time of the deadline for full application. Applicants holding both an MD and a PhD must be within 12 years of MD-graduation. Exceptions may be made for interruptions in an applicant’s academic pursuits. Applicants must be actively employed in a hematology or hematology-related research environment. Both the applicant and the applicant’s mentor should be either an EHA member, or an ASH member at the time of LOI submission and throughout the term of the award program.

Due Date: June 20, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: The purpose of this YIA is to fund physicians during the transition from a fellowship program to a faculty appointment. This is a mentored award and research projects are conducted under the guidance of a mentor. Applications are accepted from U.S. and international applicants.

Max Amount and Period: $50,000 for 1 year

Eligibility: Eligible applicants must be physicians (MD, DO, or international equivalent) in the last two years of final oncology subspecialty training and ithin 10 years of obtaining their medical degree. Applicants must be planning an investigative career in clinical oncology with a focus on lung cancer research specifically on early detection, screening, risk identification and/or prevention. Applicants must have a mentor in the proposed research field from the sponsoring institution and be an active ASCO member. Applicants must also be able to commit at least 60% of full-time effort to research.

Due Date: June 27, 2024

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.

Additional Details

RFP Snapshot: This NOSI is to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. The proposed strategies and tools should be designed to promote inclusion of historically underserved populations in clinical trials – by identifying and reducing enrollment barriers at the organizational, participant, or protocol design level.

Max Amount and Period: $125,000 for 1 year (cannot exceed the costs of the current parent award)

Eligibility: Eligible Parent Awards: R01, UG1, U01, U24, and U54. Parent award must be active, and cannot be in a no-cost extension.

Due Date: June 30, 2024 at 5PM CST

Additional Details

RFP Snapshot: These research grants will support investigators dedicated to studying bone marrow failure and advancing the understanding, prevention and treatment of bone marrow disorders in both pediatric and adult populations. In 2024, the AAMDSIF Research Grant Program will accept proposals in the following categories:
• Aplastic Anemia (focus on acquired)
• Myelodysplastic Syndromes/Neoplasms (MDS)
o MDS transition to Acute Myeloid Leukemia (AML)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Inherited bone marrow failure syndromes
In addition, proposals addressing the prevention or treatment of graft-vs-host disease (GVHD) related to hematopoietic
stem cell transplantation for bone marrow failure disease will be accepted in the 2024 grant cycle.

Max Amount and Period: $60,000 over 2 years

Eligibility: Eligible applicants will hold a MD, PhD, DO, D.Sc, or PharmD degree. Preference will be given to New Investigators who propose a project that will contribute toward their professional development in bone marrow failure disease research. New Investigators are post-doctoral fellows, Instructors, and those who have been Assistant Professors for fewer than five (5) years.

Due Date: Letter of Intent Due: June 30, 2024 at 10:59PM CST

Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at [email protected] with any questions and for assistance with reviewing/editing your proposal.